Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting 

Moderna to Host Investor Event Via Webcast
Moderna, Inc. (MRNA) announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.  

The meeting  will be held May 31 - June 4 in Chicago, IL. mRNA-4157 (V940) is being . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.